MedTrace Logo

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

NCT01861301 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2016-10-24

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well tivantinib works in treating patients with previously treated malignant mesothelioma. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Epithelioid Mesothelioma
  • Recurrent Malignant Mesothelioma
  • Sarcomatoid Mesothelioma
  • Stage II Pleural Mesothelioma
  • Stage III Pleural Mesothelioma
  • Stage IV Pleural Mesothelioma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Tivantinib

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Hedy Kindler · University of Chicago Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01861301 on ClinicalTrials.gov